Literature DB >> 15465424

Lipid and cholesterol trafficking in NPC.

Sushmita Mukherjee1, Frederick R Maxfield.   

Abstract

Niemann-Pick type C, or NPC for short, is an early childhood disease exhibiting progressive neurological degeneration, associated with hepatosplenomegaly in some cases. The disease, at the cellular level, is a result of improper trafficking of lipids such as cholesterol and glycosphingolipids (GSLs) to lysosome-like storage organelles (LSOs), which become engorged with these lipids. It is believed that the initial defect in trafficking, whether of cholesterol or a GSL, results in an eventual traffic jam in these LSOs. This leads to the retention of not only other lipids, but also of transmembrane proteins that transiently associate with the late endosomes (LE) in normal cells, on their way to other cellular destinations such as the trans-Golgi network (TGN). In this review, we discuss the biophysical properties of lipids and cholesterol that might determine their intracellular itineraries, and how these itineraries are altered in NPC cells, which have defects in the proteins NPC1 or NPC2. We also discuss some potential therapeutic directions being suggested by recent research.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465424     DOI: 10.1016/j.bbalip.2004.08.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  64 in total

Review 1.  Annexins as organizers of cholesterol- and sphingomyelin-enriched membrane microdomains in Niemann-Pick type C disease.

Authors:  Magdalena Domon; Mehmet Nail Nasir; Gladys Matar; Slawomir Pikula; Françoise Besson; Joanna Bandorowicz-Pikula
Journal:  Cell Mol Life Sci       Date:  2011-12-13       Impact factor: 9.261

2.  Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains.

Authors:  A Kodam; M Maulik; K Peake; A Amritraj; K S Vetrivel; G Thinakaran; J E Vance; S Kar
Journal:  Glia       Date:  2010-08-15       Impact factor: 7.452

Review 3.  Subcellular targeting strategies for drug design and delivery.

Authors:  Lawrence Rajendran; Hans-Joachim Knölker; Kai Simons
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 4.  ER-endosome contact sites: molecular compositions and functions.

Authors:  Camilla Raiborg; Eva M Wenzel; Harald Stenmark
Journal:  EMBO J       Date:  2015-06-03       Impact factor: 11.598

5.  2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy.

Authors:  Wensi Song; Fan Wang; Parisa Lotfi; Marco Sardiello; Laura Segatori
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

6.  Role of cathepsin D in U18666A-induced neuronal cell death: potential implication in Niemann-Pick type C disease pathogenesis.

Authors:  Asha Amritraj; Yanlin Wang; Timothy J Revett; David Vergote; David Westaway; Satyabrata Kar
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

7.  Investigation of N-aryl-3-alkylidenepyrrolinones as potential Niemann-Pick type C disease therapeutics.

Authors:  Casey C Cosner; John T Markiewicz; Pauline Bourbon; Christopher J Mariani; Olaf Wiest; Madalina Rujoi; Anton I Rosenbaum; Amy Y Huang; Frederick R Maxfield; Paul Helquist
Journal:  J Med Chem       Date:  2009-10-22       Impact factor: 7.446

8.  Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning.

Authors:  Nuno Rocha; Coenraad Kuijl; Rik van der Kant; Lennert Janssen; Diane Houben; Hans Janssen; Wilbert Zwart; Jacques Neefjes
Journal:  J Cell Biol       Date:  2009-06-29       Impact factor: 10.539

9.  ARF6-mediated endosome recycling reverses lipid accumulation defects in Niemann-Pick Type C disease.

Authors:  Jill Kuglin Schweitzer; Sean D Pietrini; Crislyn D'Souza-Schorey
Journal:  PLoS One       Date:  2009-04-14       Impact factor: 3.240

10.  New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat.

Authors:  James E Wraith; Jackie Imrie
Journal:  Ther Clin Risk Manag       Date:  2009-11-18       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.